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Abstract
BCG vaccination induces a marked increase in the IFNγ response to M.tb PPD in UK, but not
Malawian adolescents. We hypothesized that PPD-induced IFNγ following BCG vaccination
would be similar in infants in the two countries. Infants were BCG-vaccinated in the first 3-13
weeks of life. Three months post-BCG, 100% (51/51) of UK infants made an IFNγ response to
M.tb PPD, compared to 53% of Malawian infants in whom responses varied by season of birth.
We conclude that population differences in immune responses following BCG vaccination are
observed in infants, as well as in young adults.
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Introduction
Bacille Calmette-Guerin (BCG), a live attenuated strain of Mycobacterium bovis, is the only
vaccine available against tuberculosis and has been part of the WHO Expanded Program on
Immunisation (EPI) since 1974. Most countries, including Malawi, give BCG at or soon
after birth [1]. A recent policy change in the UK has led to targeted vaccination of high risk
infants [2].
Clinical trials of BCG show variable efficacy (0% to 80%) against pulmonary tuberculosis
in adults, providing good protection against pulmonary tuberculosis in the UK, but little
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protection in Malawi [3]. In infants, BCG vaccination trials show consistently high efficacy
against the severe forms of childhood tuberculosis [4].
We observed a large increase in IFNγ production to M. tuberculosis purified protein
derivative (M.tb PPD) in UK BCG-vaccinated adolescents, but a relatively small mean
change in Malawian adolescents, who made an IFNγ response to mycobacterial antigens
prior to vaccination [5]. Differing immune responses to BCG vaccination in the two
populations may be due to differing levels of prior exposure to environmental mycobacteria
[6]. We expected Malawian and UK infants to have no or minimal prior mycobacterial
exposure and therefore to make similar responses to BCG vaccination. We compared T cell
responses induced by BCG vaccination of infants in Malawi and the UK, measuring IFNγ
released into supernatants from diluted blood cultures stimulated with M.tb PPD.
Materials and Methods
Recruitment and study design
117 UK infants were recruited at health centers after informed maternal consent. Infants
(n=62) who received BCG intradermally (Danish 1331 SSI, 0.05ml) in the first 3-13 weeks
of life (median 7 weeks) were recruited in Waltham Forest Primary Care Trust (PCT), and
unvaccinated age-matched infants (n=55) from Redbridge PCT. Blood samples were taken
from vaccinated infants at three months (12-16 weeks) (n=51) and twelve months (50-56
weeks) (n=38) post-vaccination. Unvaccinated blood samples were taken at age-matched
time-points at approximately 6 months of age (n=36) and 15 months of age (n=34).
In Malawi, recruitment took place at Chilumba Rural Hospital, Karonga. After obtaining
informed consent and counselling, women were tested for HIV and offered nevirapine if
positive. A total of 615 babies were BCG-vaccinated (Danish 1331 SSI, 0.05ml); 590 were
bled at 3 months post-BCG and 552 at 12 months post-BCG. Infants were vaccinated
between 0 and 198 days of life, 62% (383/615) in the first week of life. A subset of 109
infants vaccinated between 3 and 13 weeks of life were compared with the UK infants, who
were vaccinated at the same age. Infants who were born to HIV-positive mothers (7%,
8/109) were excluded.
Sample collection took place between March 2003 and November 2005. Approval for the
study was given by the Redbridge and Waltham Forest Health Authority Local Research
Ethics Committee, the Ethics Committee of the London School of Hygiene & Tropical
Medicine, and by the National Health Sciences Research Committee of Malawi.
Whole Blood Assay and IFNγ ELISA
Whole blood assays and ELISAs for IFNγ were carried out as previously described [5, 7].
Heparinised whole blood was diluted 1 in 10 and cultured on the day of collection with the
M.tb PPD (Statens Serum Institut, Copenhagen (SSI), RT49, lot 204) at a concentration of
5μg/ml. PHA-P (Difco Laboratories/Becton Dickinson, Oxford, UK, concentration 5μg/ml)
was used as a positive control and medium alone as the negative control. Cultures were
incubated at 37°C with 5% CO2; supernatants were harvested on day 6 and stored at −70°C
until assayed for IFNγ in single 100μl samples by quantitative ELISA (detection limit 31pg/
ml).
Infants were grouped by season of their birth. In the UK, seasons were autumn (September-
November), winter (December-February), spring (March-May), summer (June-August). In
Malawi, the seasons were warm/rainy (January-May), cool/dry (June-September), and hot/
dry (October-December).
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Quality Control
We found no technical factor to explain the differences between the UK and Malawian
results (see supplementary material).
Statistical analysis
Data were double entered and verified; and analyzed using STATA 9. Negative control
(RPMI) values were subtracted from all IFNγ ELISA results. A positive IFNγ response was
defined as >62pg/ml, twice the limit of detection of the assay [8]. The proportion of infants
who made an IFNγ response was compared across groups using Chi-square tests. Non-
parametric Mann Whitney tests were used to compare IFNγ responses amongst responders.
Results
IFNγ responses to M.tb PPD
In the UK, all vaccinated infants made an IFNγ response to M.tb PPD three months post-
vaccination, and 95% twelve months post-vaccination (51/51 and 36/38 respectively).
Unvaccinated controls made no IFNγ response to M.tb PPD at either time-point (0/36, 0/34),
(P<0.0001 comparing vaccinated and unvaccinated infants at either time-point). In Malawi,
only 53% of vaccinated infants responded at three months and 48% at twelve months (41/78,
37/77 respectively). The median response in vaccinated infant responders were 1779pg/ml
(UK) and 289pg/ml (Malawi) (P<0.0001) at three months with a decline in the median
response by twelve months to 926pg/ml and 204pg/ml (Fig. 1). In Malawi, 28% of infants
did not respond at either time point, 26% responded at only three months, 20% responded at
only twelve months, and 26% responded at both time-points. IFNγ responses to M.tb PPD in
the Malawian infants who were vaccinated within the first week of life were similar: 64%
(135/210) and 43% (114/267) responded at three and twelve months respectively.
IFNγ responses to positive and negative controls
Positive responses to un-stimulated control cultures were rare (<1% UK and <8% Malawi).
Positive IFNγ responses to the mitogen PHA were seen in 88% and 74% of vaccinated UK
infants three and twelve months post-BCG. In unvaccinated controls, responses were seen in
75% of three month samples, but only 27% of twelve month samples. In Malawi, positive
IFNγ responses to PHA were seen in 51% and 45% of vaccinated infants, three and twelve
months post-BCG vaccination. There was an association between the Malawian IFNγ
responders to M.tb PPD and to PHA at three months post-BCG, with 23/38 (62%) of PHA
non-responders also being PPD non-responders, and 14/40 (38%) of PHA responders not
responding to PPD (P=0.024). This trend was also observed at twelve months post-BCG
(P=0.055). When restricted to PHA responders, the proportion of M.tb PPD responders in
Malawi was much lower (63% and 57% responded at three and twelve months post-BCG)
than in the UK (100% and 95% responded at three and twelve months post-BCG)
(P<0.0001).
Skin test responses and scar sizes
Mantoux skin tests were performed in Malawian infants 3 months post-BCG vaccination.
Forty nine percent (37/76) of infants made no skin test response (0mm), while 51% percent
made a skin test response. Of these infants, 26% (20/76) made a response between 1 and
9mm and 25% (19/76) made a response above 10mm. There is a strong association between
skin test response and IFNγ measured in supernatants stimulated with M.tb PPD (P<0.0001).
The median BCG scar size 3 months post-BCG vaccination in the UK (5mm) was larger
than in Malawi (3mm) (P<0.0001), with 100% of UK infants forming a scar while only 80%
of Malawian infants made a scar.
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Seasonal variation in responses
In Malawi, infants who were born in the hot/dry season were more likely to make an IFNγ
response (>62pg/ml) to M.tb PPD three months post-BCG vaccination (10/14, 71%) than
infants born in the cool/ dry season (12/22, 55%), who were more likely to make a response
than infants born in the warm/rainy season (19/42, 45%) (P=0.230) (Fig. 2a).
There were more high responders (>500pg/ml) in infants born in the hot and dry season
(P=0.002) (Fig. 2a). The median IFNγ response to M.tb PPD among responders also varied
by season (206pg/ml in the warm/rainy season, 240pg/ml in the cool/dry season, and
1729pg/ml in the hot/dry season) (Fig. 2b).
As the numbers of Malawian infants in this restricted data set were small, the full dataset
(615 infants) was also analysed. Three months post-vaccination, the odds of making a
positive IFNγ response were higher in the hot/dry, and cool/dry seasons than in the warm/
rainy season (Odds ratio= 5.1, P<0.001 and Odds ratio=1.8, P=0.04, respectively). Twelve
months post-vaccination, the trend was in the same direction, although weaker (Odds
ratio=2.1, p=0.005 and Odds ratio=1.3, p=0.28 respectively). The trend was similar when
using a high (>500pg/ml) cut off for an IFNγ responder, and was seen in each of the two
years of the study (data not shown). IFNγ responses to M.tb PPD by season of BCG
vaccination instead of birth gave similar results.
In the UK, median responses were higher in infants who were born in the spring (2078pg/
ml) and summer (1922pg/ml) than those born in the autumn (1342pg/ml) and winter
(1196pg/ml) (Fig 2a, b) (P=0.04).
Birthweights
Only 7% of Malawian infants were considered low birthweight, and birthweight did not
confound the association between birth season and IFNγ response. In Malawi, there was a
weak association between birthweight and IFNγ response to M.tb PPD at 3 months
(P=0.116), but not at 12 months (P=0.6).
Discussion
In this study, infants responded differently to BCG in the UK and Malawi. While all
vaccinated infants in the UK produced a strong IFNγ response three months post-BCG to
M.tb PPD, only 53% of infants in Malawi were IFNγ responders, and responses were of a
lower magnitude than UK infants. The proportion of IFNγ responders to M.tb PPD observed
three months post-BCG was maintained to twelve months in both the UK and Malawi, while
the median response decreased in the UK but not Malawi. There was greater variability in
response in Malawian infants, with 46% responding at only one time-point. In Malawi, only
47% of infants made a skin test response of >5mm three months post-BCG, although this is
higher than was seen two months post-BCG in Guinea Bissau (39% above 1mm) [9]. Scars
were present at 3 months post-BCG in only 80% of Malawian infants, and were smaller than
the median size of scar in the UK. Unvaccinated controls in the UK did not produce any
detectable IFNγ response to M.tb PPD at either time-point.
Differences observed in the responses to BCG vaccination in UK and Malawian adolescents
have been attributed to the high proportion of Malawian individuals already exposed and
sensitised to a variety of environmental mycobacterial antigens prior to vaccination [6].
Masking or blocking of the BCG response through exposure to environmental mycobacteria
remains a plausible explanation, although we were unable to demonstrate a relationship
between prior IFNγ responses to specific environmental mycobacteria antigens, and BCG-
attributable changes in IFNγ to M.tb PPD in UK or Malawian adolescents [10]. The
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differences observed in the UK and Malawian infants are unlikely to be due to prior
environmental exposure, as Malawian infants vaccinated in the first week of life had low
IFNγ responses to M.tb PPD.
There has been no formal evaluation of neonatal BCG protection against childhood forms of
tuberculosis in Malawi. Given the large population differences observed between the
immune responses to BCG vaccination in the UK and Malawian infants it is possible that
BCG vaccination does not offer equal protection to infants in different countries. Studies of
neonatal BCG in some other African countries, such as South Africa and The Gambia, have
shown strong IFNγ responses induced in similar assays. In The Gambia, IFNγ responses to
M.tb PPD measured in PBMC cultures were similar to adult responses [11]. In South Africa,
IFNγ was measured by flow cytometry following stimulation of whole blood with live BCG,
ten weeks post-vaccination [12]. However a randomised trial in Guinea Bissau, examining
the effect of Vitamin A supplementation on immune response to BCG using a similar whole
blood assay to ours found comparably low median IFNγ responses (199pg/ml to M.tb PPD),
similar to the Malawian responses in our study [9].
IFNγ responses to PHA were lower than expected at three and twelve months post-BCG in
UK and Malawian infants. In the UK, whereas 100% of vaccinated infants made a response
to M.tb PPD three months post-BCG, only 88% of these infants made a response to PHA. In
Malawi, responses to PHA were low, with only 51% of the infants responding three months
post-BCG. In future studies Staphylococcal enterotoxin B (SEB) [12] may be a better
positive control to use in infants than 5ug/ml PHA.
IFNγ responses to M.tb PPD three months post-BCG varied with the season of birth of the
infant. In Malawi, the proportion of IFNγ responders was higher in infants born during the
hot/dry season, and the median response amongst responders was similar to the median
response in the UK. In the UK, a difference in IFNγ response to M.tb PPD by season of birth
was also observed, with greater responses in the summer. Seasonal variation in responses to
rabies and typhoid vaccinations have been reported in the Gambia and Pakistan [13], while a
recent study of BCG-vaccinated infants in The Gambia showed higher proportions of CD4 T
cells expressing CD154 at 12 months of age in infants born in the wet compared to the dry
season [14]. Our observed seasonal variation in IFNγ responses to BCG vaccination suggest
that environmental factors play a role in vaccine induced immunity. These could include
seasonal differences in the burdens of infections, such as malaria or respiratory infections in
the wet season in Malawi, and common respiratory infections in the winter in the UK. The
varying responses in Malawi could also be due to nutritional factors which vary by season
depending on availability of food.
Other factors which may also be influencing the different responses seen in Malawian and
UK infants include differences in the maturation of the immune system, T cell clonal
responses[15], burdens of maternal infectious diseases or schedules of other vaccinations.
This is the first study which shows that population differences in responses to BCG
vaccination occur in infants as well as adults. This finding has important implications for the
use of BCG and the development and testing of future TB vaccines designed to boost
immune responses induced by BCG. It may also have implications for immune responses to
other infant vaccinations, and warrants further study.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. IFNγ responses to M.tb PPD
a) Histograms showing IFNγ responses to M.tb PPD in unvaccinated UK infants, vaccinated
UK infants, and vaccinated Malawian infants three and twelve months post BCG
vaccination and age-matched for unvaccinated controls. b) Box and whisker plots showing
IFNγ responses to M.tb PPD in vaccinated UK and Malawian infants three and twelve
months post BCG vaccination.
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Figure 2. IFNγ responses to M.tb PPD three months post BCG vaccination by season of birth
a) Bar charts showing percentage of low responders (62-500pg/ml) and high responders
(>500pg/ml) by season in the UK and Malawi. In the UK, responses are shown for Autumn
(Sept, Oct, Nov), Winter (Dec, Jan, Feb), Spring (Mar, Apr, May), Summer Jun, Jul, Aug).
In Malawi, seasons are warm and rainy (Jan, Feb, Mar, Apr, May), cool and dry (Jun, Jul,
Aug, Sep), hot and dry (Oct, Nov, Dec).
b) Box and whisker plots showing IFNγ responses to M.tb PPD in Malawi and the UK by
season. (UK n=51, Malawi n=78).
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